Pandemic Influenza

Positive preclinical results reported on vaccine for pandemic influenza

Published in Vaccine Weekly, September 21st, 2005

Novavax, Inc., (NVAX) reported preclinical results on the company's novel Virus-Like Particle (VLP) influenza vaccine.

Novavax's biological group led by Dr. Gale Smith, together with Dr. Tumpey and Dr. Bu from the U.S. Centers for Disease Control and Prevention (CDC), published the detailed results in the August 15, 2005, online edition of the journal Vaccine. The study demonstrates that a H9N2 influenza virus (avian flu) vaccine produced with the company's proprietary VLP technology is effective in protecting animals when challenged with live H9N2 influenza virus.

The work, published in the peer-reviewed journal Vaccine, was completed...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (2005-09-21)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry